AU Patent

AU2016368622B2 — Pharmaceutical composition comprising a potent inhibitor of URAT1

Assigned to AstraZeneca AB · Expires 2022-09-08 · 4y expired

What this patent protects

The present invention relates to pharmaceutical compositions containing 2-((3-(4- cyanonaphthalen-1-yl)pyridine-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the "Agent"), more particularly to orally deliverable compos…

USPTO Abstract

The present invention relates to pharmaceutical compositions containing 2-((3-(4- cyanonaphthalen-1-yl)pyridine-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the "Agent"), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.

Drugs covered by this patent

Patent Metadata

Patent number
AU2016368622B2
Jurisdiction
AU
Classification
—
Expires
2022-09-08
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.